Beijing, China and Vienna VA, USA – On June 8 (Beijing Time), the Quality Brands Protection Committee of CAEFI (QBPC) and the Pharmaceutical Security Institute (PSI) signed a Memorandum of Understanding (MOU) to facilitate cooperation between the two prestigious organizations.
PSI, established in 2002, is a not-for-profit, membership organization dedicated to protecting the public health, sharing information on the counterfeiting of pharmaceuticals and initiating enforcement actions through the appropriate authorities. Its membership includes thirty-nine pharmaceutical manufacturers from many nations. Founded in 2000, QBPC is the most influential member-driven organization of right holders operating in China, focusing on improving IP legal framework and enforcement in China. Currently it is comprised of 200+ member companies worldwide.
During the virtual signing ceremony, QBPC Vice Chair Ji Ying made opening remarks that QBPC had been working closely with the enforcement authorities, right holders, online marketplaces/social media, and international industry bodies with an aim to safeguard the IPR protection environment in China. Moreover, QBPC had 17 Industry Working Groups (IWGs) including the Pharmaceutical & Medical Devices IWG, which was composed of more than 20 famous and influential companies in the industry. As the coordinator of this IWG, she had been working closely with the police, procurators, and Customs. At the same time, the IWG carried out a series of activities focusing on specific issues, such as conducting regular discussions on common topics; organizing group visits to online marketplaces and social media to collect and discuss hot issues; carrying out capacity training and tendency sharing with key enforcement authorities, etc. These initiatives were aimed at combating counterfeits and illicit trading, protecting the patients, and ensuring that patients had access to the right medicine they needed.
In addition, Ji Ying mentioned that QBPC Pharmaceutical and Medical Devices IWG and PSI were not strangers and had launched some joint projects a few years ago. QBPC looked forward to this partnership with PSI, which had a strong pharmaceutical background. The collaboration between both organizations would enhance communication and sharing of information between each other, expand the coverage of capacity building training, discuss issues of common concern, and further shape the healthy environment to protect both patients and right holders through close cooperation in order to achieve a win-win situation.
Subsequently, QBPC Chair Michael Ding shared priorities of QBPC from four dimensions. He was excited to sign the MOU with PSI as such global collaboration was the said QBPC focus. Through such collaboration, QBPC expected to share the best practices in China with member company headquarters and international IP community, meanwhile, bring constructive comments back to China for further improvement. By signing the MOU, he was looking forward to more substantive cooperation with PSI to jointly promote a better IP protection business and legal environment, especially in the pharmaceutical industry, so as to benefit the members.
At the closure of the event, both CEO of PSI Mr. Todd Ratcliffe and Asia Pacific Regional Director Ramesh Raj Kishore respectively expressed their approval of the ongoing relationship and excitedly looked forward to increased cooperation between the two parties. As the representatives of both parties displayed the signed MOU documents, the signing ceremony was successfully concluded.